Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
<strong>Background<br></strong> The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess ho...
| প্রধান লেখক: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| অন্যান্য লেখক: | |
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
Elsevier
2023
|
| _version_ | 1826311971813720064 |
|---|---|
| author | Staplin, N Mayne, MJ Abat, S Abd Rahman, R Abdul Cader, R Abdul Hafidz, MI Abdul Wahab, MZ Abdullah, NK Abdul-Samad, T Abe, M Abraham, N Acheampong, S Achiri, P Acosta, JA Adeleke, A Adell, V Adewuyi-Dalton, R Adnan, N Africano, A Agharazii, M Aguilar, F Aguilera, A Ahmad, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad Miswan, N Ahmad Rosdi, H Ahmed, I Ahmed, S Aiello, J Aitken, A AitSadi, R Aker, S Akimoto, S Akinfolarin, A Akram, S Alberici, F Albert, C Aldrich, L Alegata, M Alexander, L Alfaress, S Alhadj Ali, M Ali, A Alicic, R Aliu, A Almaraz, R Almasarwah, R Almeida, J Aloisi, A |
| author2 | Judge, P |
| author_facet | Judge, P Staplin, N Mayne, MJ Abat, S Abd Rahman, R Abdul Cader, R Abdul Hafidz, MI Abdul Wahab, MZ Abdullah, NK Abdul-Samad, T Abe, M Abraham, N Acheampong, S Achiri, P Acosta, JA Adeleke, A Adell, V Adewuyi-Dalton, R Adnan, N Africano, A Agharazii, M Aguilar, F Aguilera, A Ahmad, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad Miswan, N Ahmad Rosdi, H Ahmed, I Ahmed, S Aiello, J Aitken, A AitSadi, R Aker, S Akimoto, S Akinfolarin, A Akram, S Alberici, F Albert, C Aldrich, L Alegata, M Alexander, L Alfaress, S Alhadj Ali, M Ali, A Alicic, R Aliu, A Almaraz, R Almasarwah, R Almeida, J Aloisi, A |
| author_sort | Staplin, N |
| collection | OXFORD |
| description | <strong>Background<br></strong>
The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.
<br><strong>
Methods<br></strong>
EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110.
<br><strong>
Findings<br></strong>
Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1).
<br><strong>
Interpretation<br></strong>
In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease.
<br><strong>
Funding<br></strong>
Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council. |
| first_indexed | 2024-03-07T08:20:38Z |
| format | Journal article |
| id | oxford-uuid:bb63034e-4871-42ef-9d33-4c44f303e08d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:20:38Z |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:bb63034e-4871-42ef-9d33-4c44f303e08d2024-01-24T13:53:08ZImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bb63034e-4871-42ef-9d33-4c44f303e08dEnglishSymplectic ElementsElsevier2023Staplin, NMayne, MJAbat, SAbd Rahman, RAbdul Cader, RAbdul Hafidz, MIAbdul Wahab, MZAbdullah, NKAbdul-Samad, TAbe, MAbraham, NAcheampong, SAchiri, PAcosta, JAAdeleke, AAdell, VAdewuyi-Dalton, RAdnan, NAfricano, AAgharazii, MAguilar, FAguilera, AAhmad, MAhmad, MKAhmad, NAAhmad, NHAhmad, NIAhmad Miswan, NAhmad Rosdi, HAhmed, IAhmed, SAiello, JAitken, AAitSadi, RAker, SAkimoto, SAkinfolarin, AAkram, SAlberici, FAlbert, CAldrich, LAlegata, MAlexander, LAlfaress, SAlhadj Ali, MAli, AAlicic, RAliu, AAlmaraz, RAlmasarwah, RAlmeida, JAloisi, AJudge, PThe EMPA-KIDNEY Collaborative Group<strong>Background<br></strong> The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. <br><strong> Methods<br></strong> EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. <br><strong> Findings<br></strong> Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). <br><strong> Interpretation<br></strong> In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. <br><strong> Funding<br></strong> Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council. |
| spellingShingle | Staplin, N Mayne, MJ Abat, S Abd Rahman, R Abdul Cader, R Abdul Hafidz, MI Abdul Wahab, MZ Abdullah, NK Abdul-Samad, T Abe, M Abraham, N Acheampong, S Achiri, P Acosta, JA Adeleke, A Adell, V Adewuyi-Dalton, R Adnan, N Africano, A Agharazii, M Aguilar, F Aguilera, A Ahmad, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad Miswan, N Ahmad Rosdi, H Ahmed, I Ahmed, S Aiello, J Aitken, A AitSadi, R Aker, S Akimoto, S Akinfolarin, A Akram, S Alberici, F Albert, C Aldrich, L Alegata, M Alexander, L Alfaress, S Alhadj Ali, M Ali, A Alicic, R Aliu, A Almaraz, R Almasarwah, R Almeida, J Aloisi, A Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title_full | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title_fullStr | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title_full_unstemmed | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title_short | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
| title_sort | impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease secondary analyses of the empa kidney trial |
| work_keys_str_mv | AT staplinn impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT maynemj impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abats impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdrahmanr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdulcaderr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdulhafidzmi impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdulwahabmz impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdullahnk impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abdulsamadt impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abem impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT abrahamn impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT acheampongs impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT achirip impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT acostaja impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT adelekea impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT adellv impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT adewuyidaltonr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT adnann impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT africanoa impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT agharaziim impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aguilarf impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aguileraa impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadm impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadmk impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadna impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadnh impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadni impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadmiswann impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmadrosdih impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmedi impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT ahmeds impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aielloj impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aitkena impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aitsadir impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT akers impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT akimotos impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT akinfolarina impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT akrams impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT albericif impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT albertc impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aldrichl impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alegatam impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alexanderl impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alfaresss impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alhadjalim impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alia impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT alicicr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aliua impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT almarazr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT almasarwahr impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT almeidaj impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial AT aloisia impactofprimarykidneydiseaseontheeffectsofempagliflozininpatientswithchronickidneydiseasesecondaryanalysesoftheempakidneytrial |